Underestimated Prediabetic Biomarkers: Are We Blind to Their Strategy?
Carla Luís1,2,3, Raquel Soares2,3, Pilar Baylina1,3,4
1Laboratory of Medical & Industrial Biotechnology (LABMI)-Porto Research, Technology and Innovation Center (PORTIC), Porto, Portugal.
Abstract:
Type 2 Diabetes (T2D) is currently one of the fastest growing health challenging, a non-communicable disease result of the XXI century lifestyle. Given its growing incidence and prevalence, it became increasingly imperative to develop new technologies and implement new biomarkers for early diagnosis in order to promote lifestyle changes and thus cause a setback of the disease. Promising biomarkers have been identified as predictive of T2D development; however, none of them have yet been implemented in clinical practice routine. Moreover, many prediabetic biomarkers can also represent potential therapeutical targets in disease management. Previous studies have identified the most popular biomarkers, which are being thoroughly investigated. However, there are some biomarkers with promising preliminary results with limited associated studies; hence there is still much to be understood about its mechanisms and associations in T2D pathophysiology. This work identifies and discusses the promising results of Galectin-3, Ophthalmate and Fetuin-A.
Insights
New biomarkers like Galectin-3, Ophthalmate, and Fetuin-A show promise for early Type 2 Diabetes (T2D) detection. Further research is needed to understand their role in T2D pathophysiology and clinical application.
Area of Science:
- Endocrinology and Metabolism
- Biomarker Discovery
- Non-communicable Diseases
Background:
- Type 2 Diabetes (T2D) is a rapidly growing global health challenge linked to modern lifestyles.
- Early diagnosis and intervention are crucial for managing T2D prevalence and incidence.
- Existing predictive biomarkers for T2D are not yet routine in clinical practice.
Purpose of the Study:
- To identify and discuss promising biomarkers for early Type 2 Diabetes (T2D) detection.
- To explore the potential of Galectin-3, Ophthalmate, and Fetuin-A as T2D biomarkers.
- To highlight the need for further research into novel biomarkers and their mechanisms.
Main Methods:
- Review and synthesis of existing literature on T2D biomarkers.
- Focus on preliminary findings for Galectin-3, Ophthalmate, and Fetuin-A.
- Discussion of the pathophysiological associations and clinical potential of these biomarkers.
Main Results:
- Galectin-3, Ophthalmate, and Fetuin-A show promising preliminary results as potential biomarkers for T2D.
- These biomarkers may also serve as therapeutic targets for managing prediabetes and T2D.
- Limited studies exist for these specific biomarkers, indicating a need for more extensive research.
Conclusions:
- Galectin-3, Ophthalmate, and Fetuin-A represent promising avenues for T2D early diagnosis.
- Further investigation is essential to elucidate their mechanisms and validate their clinical utility.
- Advancing biomarker research is key to improving T2D prevention and management strategies.
Related Concept Videos
Diabetes: Symptoms, Diagnosis, and Complications
Diabetes Mellitus: Type 2 and Gestational
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Errors occurring during blood pressure monitoring
Several factors...
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Coronary Artery Disease I: Introduction


